Novo Nordisk A/S

More Details of Novo Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

Company codeNVO

Company nameNovo Nordisk A/S

IPO dateMay 17, 1974

Founded at1931

CEOMr. Lars Fruergaard Joergensen

Number of employees76302

Security typeOrdinary Share

Fiscal year-endMay 17

AddressNovo Alle 1

CityBAGSVAERD

Stock exchangeThe Toronto Stock Exchange

CountryDenmark

Postal code2880

Phone4544448888

Websitehttps://www.novonordisk.com/

Company codeNVO

IPO dateMay 17, 1974

Founded at1931

Company Executives

Name

Name/Position

Position

Shareholding

Change

Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Ms. Tania Sabroe

Executive Vice President - Global People, Organisation and Communication

--

Dr. Martin Holst Lange

Executive Vice President - Development

--

Mr. Andreas Fibig

Independent Director

--

Dr. Sylvie L. Gregoire, Pharm.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Thilde Hummel Bogebjerg

Executive Vice President - Quality, IT & Environmental Affairs

--

Mr. Jacob Martin Wiborg Rode

Head of Investor Relations

--

Mr. Helge Lund

Independent Chairman of the Board

--

Mr. David Moore

Executive Vice President - US Operations and Business Development

--

Mr. Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

--

Mr. Thomas Rantzau

Director, Employee Representative

--

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Total GLP-1

21.63B

51.35%

Obesity (Saxenda®)

9.45B

22.43%

Long-acting insulin

2.77B

6.58%

Fast-acting insulin

2.69B

6.38%

Rare blood disorders

1.76B

4.18%

Other

3.83B

9.08%

By RegionUSD

Name

Revenue

Proportion

USA

24.28B

57.64%

EMEA

8.76B

20.80%

Rest of World

4.83B

11.48%

Region China

2.68B

6.37%

Canada

1.56B

3.71%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Total GLP-1

21.63B

51.35%

Obesity (Saxenda®)

9.45B

22.43%

Long-acting insulin

2.77B

6.58%

Fast-acting insulin

2.69B

6.38%

Rare blood disorders

1.76B

4.18%

Other

3.83B

9.08%

Shareholder

Update time: Tue, Mar 11

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Jennison Associates LLC

0.59%

GQG Partners, LLC

0.39%

Fisher Investments

0.38%

Loomis, Sayles & Company, L.P.

0.34%

Fayez Sarofim & Co.

0.34%

Other

97.96%

Shareholder Statistics

Shareholder

Proportion

Jennison Associates LLC

0.59%

GQG Partners, LLC

0.39%

Fisher Investments

0.38%

Loomis, Sayles & Company, L.P.

0.34%

Fayez Sarofim & Co.

0.34%

Other

97.96%

Type

Shareholder

Proportion

Investment Advisor

5.20%

Investment Advisor/Hedge Fund

2.92%

Research Firm

0.82%

Hedge Fund

0.63%

Pension Fund

0.28%

Insurance Company

0.21%

Bank and Trust

0.17%

Family Office

0.02%

Family Office

0.02%

Other

89.72%

Institutional Shareholding

Update time: Thu, Feb 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2667

350.24M

10.41%

+3.15M

2024Q4

2676

348.53M

10.35%

+330.19K

2024Q3

2529

339.29M

10.15%

-6.04M

2024Q2

2456

341.24M

10.21%

+6.87M

2024Q1

2291

330.25M

9.75%

+10.89M

2023Q4

2037

314.57M

9.30%

+1.47M

2023Q3

1826

307.14M

8.91%

+4.22M

2023Q2

1692

293.83M

8.50%

+768.69K

2023Q1

1603

284.38M

8.30%

-15.92M

2022Q4

1498

293.73M

8.57%

+2.21M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Jennison Associates LLC

19.94M

0.59%

-251.15K

-1.24%

Dec 31, 2024

GQG Partners, LLC

12.99M

0.39%

+5.56M

+74.70%

Dec 31, 2024

Fisher Investments

12.64M

0.38%

-664.99K

-5.00%

Dec 31, 2024

Loomis, Sayles & Company, L.P.

11.57M

0.34%

+2.95M

+34.18%

Dec 31, 2024

Fayez Sarofim & Co.

11.38M

0.34%

-832.64K

-6.82%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.89M

0.29%

-7.78M

-44.05%

Dec 31, 2024

Managed Account Advisors LLC

9.39M

0.28%

+1.11M

+13.43%

Dec 31, 2024

Folketrygdfondet

8.90M

0.26%

+40.31K

+0.45%

Dec 31, 2024

Renaissance Technologies LLC

8.31M

0.25%

+123.68K

+1.51%

Dec 31, 2024

Capital International Investors

6.75M

0.2%

-204.59K

-2.94%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

Novo Nordisk A/S (B Shares) ADRhedged

100%

Roundhill GLP-1 & Weight Loss ETF

15.18%

Amplify Weight Loss Drug & Treatment ETF

13.08%

VanEck Pharmaceutical ETF

4.86%

iShares Long-Term US Equity Active ETF

4.59%

AdvisorShares Gerber Kawasaki ETF

4.03%

TrueShares Technology, AI & Deep Learning ETF

3.12%

Clockwise Core Equity & Innovation ETF

2.63%

PGIM Jennison Better Future ETF

2.37%

SP Funds S&P World (ex-US) ETF

2.34%

Novo Nordisk A/S (B Shares) ADRhedged

Proportion100%

Roundhill GLP-1 & Weight Loss ETF

Proportion15.18%

Amplify Weight Loss Drug & Treatment ETF

Proportion13.08%

VanEck Pharmaceutical ETF

Proportion4.86%

iShares Long-Term US Equity Active ETF

Proportion4.59%

AdvisorShares Gerber Kawasaki ETF

Proportion4.03%

TrueShares Technology, AI & Deep Learning ETF

Proportion3.12%

Clockwise Core Equity & Innovation ETF

Proportion2.63%

PGIM Jennison Better Future ETF

Proportion2.37%

SP Funds S&P World (ex-US) ETF

Proportion2.34%

Dividend

A total of 21.09B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Aug 06, 2024

NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Aug 26, 2024

Aug 16, 2024

Jan 31, 2024

NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024

Mar 25, 2024

Apr 02, 2024

Mar 22, 2024

Aug 10, 2023

NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023

Aug 21, 2023

Aug 29, 2023

Aug 18, 2023

Feb 02, 2023

NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023

Mar 27, 2023

Apr 04, 2023

Mar 24, 2023

Aug 04, 2022

NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022

Aug 15, 2022

Aug 23, 2022

Aug 12, 2022

Mar 02, 2022

NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022

Mar 28, 2022

Apr 05, 2022

Mar 25, 2022

Aug 05, 2021

NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021

Aug 17, 2021

Aug 25, 2021

Aug 16, 2021

Feb 22, 2021

NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021

Mar 29, 2021

Apr 07, 2021

Mar 26, 2021

Aug 06, 2020

NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020

Aug 17, 2020

Aug 25, 2020

Aug 14, 2020

Feb 06, 2020

NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020

Mar 30, 2020

Apr 07, 2020

Mar 27, 2020

Stock Split

Date

Type

Ratio

Aug 14, 2023

Split

1>2

Date

Type

Ratio

Aug 14, 2023

Split

1>2

61.600USD

Novo Nordisk A/S

61.600

Overview

Company